Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412055 | 0.76 | LMNA (0.33) | LMNAKMT2AALDH1A1CYP1A2 | |
| SCHEMBL4405008 | 0.76 | LMNA (0.33) | LMNAKMT2AALDH1A1 | |
| SCHEMBL4405424 | 0.76 | LMNA (0.33) | LMNAKMT2AALDH1A1 | |
| SCHEMBL4407082 | 0.76 | LMNA (0.33) | LMNAKMT2AALDH1A1 | |
| SCHEMBL4412072 | 0.76 | LMNA (0.33) | LMNAKMT2AALDH1A1 | |
| SCHEMBL4410962 | 0.74 | ALDH1A1 (0.35) | MAPK1LMNAKMT2AALDH1A1 | |
| SCHEMBL4408965 | 0.74 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL95236 | 0.73 | — | — | |
| SCHEMBL4411106 | 0.72 | LMNA (0.31) | MAPK1LMNAKMT2AALDH1A1 | |
| SCHEMBL4415158 | 0.72 | LMNA (0.31) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106302-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2022-04-07 | — | — | US | disclosed |
| US-11028078-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190040046-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-07 | — | — | US | disclosed |
| US-9133235-B2 | Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders | OCERA THERAPEUTICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100093720-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080287371-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX | TRANZYME PHARMA INC. | 2008-11-20 | — | — | US | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-7160886-B2 | Acylated piperazine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093720-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | MLNR, GIPR, GPR39 | MAPK1 915/4885LMNA 4810/4885KMT2A 4427/4885 |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MAPK1 1219/4885LMNA 800/4885KMT2A 2207/4885 |
| US-20190040046-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | SHH, GLI1, KDR | MAPK1 1948/4885LMNA 4868/4885KMT2A 3182/4885 |
| US-20220106302-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | CYP3A4, SHH, GLI1 | MAPK1 3835/4885LMNA 4875/4885KMT2A 3683/4885 |
| US-11028078-B2 | Itraconazole analogs and use thereof | SHH, GLI1, KDR | MAPK1 1948/4885LMNA 4868/4885KMT2A 3182/4885 |
| US-20080287371-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX | MLNR, CCKAR, CCKBR | MAPK1 1146/4885LMNA 4603/4885KMT2A 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.